Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Minerva Neurosciences, Inc

Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Minerva Neurosciences Reports Third Quarter 2022 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Minerva Neurosciences Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
From Minerva Neurosciences, Inc
Via GlobeNewswire
Tickers NERV
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.